LPCN1144

The FDA has mandated new labeling changes for testosterone products based on the TRAVERSE trial, which demonstrated cardiovascular safety in high-risk men with hypogonadism.

OliX Pharmaceuticals has secured a landmark $630 million licensing agreement with Eli Lilly for OLX75016, an RNAi-based therapeutic targeting MASH and obesity.

The FDA has granted Fast Track designation to Lipocine's LPCN 1148 for treating sarcopenia in patients with decompensated cirrhosis, addressing an unmet medical need.

Lipocine Inc., a clinical-stage biopharmaceutical company, is making significant strides in the treatment of metabolic and endocrine disorders through its proprietary drug delivery technology. The company has announced various clinical trial results, financial updates, and strategic partnerships aimed at advancing its pipeline of innovative treatments.

The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.